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A b s t r a c t
Background: Renalase is a catecholamine-metabolising enzyme, but its possible association with atrial fibrillation (AF) remains 
unknown. 
Aim: We sought to evaluate plasma renalase concentration in patients with AF undergoing pulmonary vein isolation (PVI) with 
respect to AF clinical characteristics, left atrial (LA) remodelling, and PVI efficacy.
Methods: This case-control study included 69 patients (median age 58 years) with either paroxysmal (89%) or persistent 
(11%) AF, referred for PVI, and a control group consisting of 15 patients without AF, matched for age, sex, and comorbidi-
ties. An evaluation of transthoracic echocardiography with LA speckle tracking and plasma renalase concentration using an 
enzyme-linked immunosorbent assay was performed. AF recurrence was defined as any AF episode on seven-day electro-
cardiographic monitoring at six-month follow-up. 
Results: Renalase level was higher in the study group than in the control group (mean 27.99 vs. 21.48 μg/mL, p = 0.004), 
but it was lower in patients with persistent AF (19.05 vs. 28.77 μg/mL; p = 0.023) and among patients with AF episodes di-
rectly preceding PVI (24.50 vs. 29.66 μg/mL; p = 0.04). Renalase concentration within the first quartile was associated with 
higher mean heart rate (70 vs. 61 bpm, p = 0.029), greater AF burden (36.9% vs. 9.3%, p = 0.027), greater LA diameter 
(41.1 vs. 37.9 mm, p = 0.011), and a trend towards less negative global LA strain (–9.4 vs. –13.5, p = 0.082). Logistic regres-
sion revealed that global four-chamber LA strain was the only independent predictor of renalase variability (p = 0.0045). 
Renalase concentration did not predict AF recurrence at six-month follow-up (area under curve [AUC] = 0.614, p = 0.216). 
Conclusions: Low renalase level may be associated with impaired rate control, higher AF burden, and advanced LA remodel-
ling in AF patients undergoing PVI, but it does not predict sinus rhythm maintenance. 
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INTRODUCTION
Atrial fibrillation (AF) remains one of the leading challenges 
of contemporary medicine due to its widespread prevalence 
and ischaemic stroke risk [1]. None of the hitherto published 
studies has unequivocally proven the superiority of either 
rhythm or rate control strategy in terms of mortality reduc-
tion [2, 3]; however, in patients with new-onset AF, especially 
among young adults, preservation of sinus rhythm is frequently 
preferred on account of the prevention of electrical left atrial 
(LA) remodelling [4]. Rhythm control strategy incorporates 
antiarrhythmic drugs, pharmacological or electrical cardio-
version, and pulmonary vein isolation (PVI). Despite rapid 
improvement of technology and accessibility, PVI leads to 
objective improvement (absence of AF or reduction of AF 
episodes duration and intensity) in just 60% of patients [5, 6]. 
Due to possible procedural complications and high cost, the 
cornerstone of successful PVI relies on adequate qualification 
and selection of procedural responders. 
Several predictors of AF recurrence have been estab-
lished, such as the number of comorbidities, AF episode 
duration, CHADS2 and CHA2DS2-VASc scores [7, 8], LA 
diameter [9] or volume [10], LA fibrosis as assessed by late 
gadolinium enhancement on cardiac magnetic resonance 
[11, 12], LA global longitudinal strain [13], or LA appendage 
emptying flow velocity [14]. Also, several biomarkers served 
as promising predictors of adverse LA remodelling and sinus 
rhythm maintenance, including natriuretic peptides [15, 16], 
C-reactive protein and interleukin-6 [17], galectin-3 [18], 
endothelin-1 [16, 19], and cardiac troponin [10, 16]. How-
ever, none of the listed biomarkers alone conferred sufficient 
diagnostic power to predict the outcome of AF treatment.
Renalase represents a circulating protein, expressed 
primarily in proximal tubular cells and the myocardium [20, 
21]. Although its interference with metabolism of catechola-
mines is disputed, renalase has been shown to inversely cor-
relate with peripheral and central blood pressure [22]. Single 
nucleotide polymorphisms within the renalase gene were 
documented to be related with primary arterial hypertension 
[23], ventricular hypertrophy, and left ventricular dysfunction 
[24]. Exogenous renalase protected myocardial cells against 
ischaemia-reperfusion injury in an animal model [25]. We 
therefore speculated that renalase may play a role in LA atrial 
remodelling and thereby potentially modulate response to PVI 
and facilitate sinus rhythm maintenance.
Thus, the purpose of the study was to evaluate plasma 
renalase concentration in patients with paroxysmal or persis-
tent AF undergoing PVI with regard to clinical characteristics 
of AF and echocardiographic indices of adverse left atrial 
remodelling and recurrence.
METHODS
The project was conducted as a case-control study. The study 
flow-chart is depicted in Figure 1. Sixty-nine patients with 
either paroxysmal or persistent AF undergoing catheter-based 
percutaneous PVI during index hospitalisation were enrolled 
into the study group, which was furthered categorised into 
four subgroups depending on the quartile of peripheral vein 
renalase distribution. The control group consisted of 15 vol-
unteer patients consulted in the cardiology clinic, without 
current or former AF, as verified by 24-h electrocardiographic 
monitoring, matched for sex, age, and comorbidities with the 
study group. In both groups different clinical and echocardio-
graphic parameters, as well as plasma renalase concentration 
were evaluated.
Patients in the study group were followed up for six 
months on an outpatient basis. At this time point, a seven-day 
electrocardiographic monitoring was performed to detect pos-
sible recurrence of AF and to establish six-month follow-up AF 
burden. The primary endpoint was any form of AF detected 
on Holter monitoring at six months. 
Patients in both the study and control groups were 
diligently queried and previous discharge summaries were 
analysed to elucidate the following exclusion criteria: a) his-
tory of transient ischaemic attack or stroke of any kind; b) 
active neoplastic disease; c) inflammatory disease within the 
past three months; d) chronic kidney disease with estimated 
glomerular filtration rate < 30 mL/min/1.73 m2; e) liver dys-
function (any hepatic aminotransferase > 3 × upper reference 
limit); f) valvular heart disease (moderate or severe); g) left 
ventricular ejection fraction < 45%, congestive heart failure; 
and h) idiopathic cardiomyopathy.
The study was conducted in accordance with the Dec-
laration of Helsinki and was approved by the Ethics Commit-
tee of the Medical University of Silesia in Katowice. All the 
patients gave written consent for participation in the study 
prior to enrolment.
Laboratory tests and renalase concentration
Blood samples (10 mL) were collected: a) from the antecubital 
vein, on admission, in all study participants (study and control 
groups); b) from the femoral vein, at the beginning of the PVI 
procedure, in the study group.
Blood samples were assayed for plasma renalase con-
centration by means of enzyme-linked immunosorbent assay 
(ELISA) method (Cloud-Clone Corp., Houston, TX, USA). 
EDTA was used as an anticoagulant, and samples were cen-
trifuged for 15 min at 1000 × g at 2oC to 8oC within 15 min 
of collection. The samples were stored at –80oC with no 
freeze-thaw cycles and assayed within three months follow-
ing acquisition according to the manufacturer’s instructions.
Electrocardiographic Holter monitoring
Prolonged 24-h electrocardiographic monitoring was per-
formed during index hospitalisation prior to PVI in the study 
group and on an outpatient basis in the control group. At six 
months the patients in the study group underwent a seven-day 
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Holter electrocardiographic monitoring to assess individual 
response to PVI. AF burden was defined as the percentage of 
overall duration of AF episodes in relation to the total time of 
recording. The monitoring was performed using the Pathfinder 
SL system (Spacelabs Healthcare, Deerfield, WI, USA).
Transthoracic echocardiography  
and speckle tracking imaging
Routine echocardiographic check-up was conducted us-
ing Epiq 7G (Philips, Andover, MA, USA) with a 2.5-MHz 
probe in two-dimensional (2D), M-, and Doppler modes by 
a single investigator. Offline 2D speckle tracking imaging was 
employed to calculate two-chamber and four-chamber LA 
global longitudinal strains using EchoPAC Software version 
112.0.0 (GE Healthcare, Horten, Norway). Subsequently, 
carotid scans were performed using a Logic 7, GE ultrasound 
machine with a 7- to 12-MHz linear array transducer and then 
analysed using a quantitative analysis package manufactured 
by Siemens. The scans were acquired perpendicularly to the 
carotid artery, and measurements of intima-media thickness 
were made at 1-mm intervals over a 10-mm segment of the 
vessel. The maximal and mean intima-media thickness meas-
urements were determined for the proximal and distal walls 
of the left and right common carotid arteries. 
Definitions
Paroxysmal AF was defined as self-terminating within 48 h or 
cardioverted within seven days from the onset of arrhythmia, 
while persistent AF was defined as arrhythmia lasting for more 
than seven days [1]. Arterial hypertension was diagnosed if 
blood pressure was above the threshold of 140/90 mmHg 
on two separate measurements during index hospitalisation 
or in the event of former arterial hypertension diagnosis or 
antihypertensive medication use. Diabetes mellitus/impaired 
fasting glucose/impaired glucose tolerance were analysed 
jointly. Diabetes was diagnosed on the condition that fast-
ing blood exceeded 125 mg/dL on two separate days or if 
a patient received insulin or oral hypoglycaemic agents. Esti-
mated glomerular filtration rate was calculated according to 
Cockroft-Gault formula.
Figure 1. Study flow-chart including the study and control groups; AF — atrial fibrillation; CKD — chronic kidney disease;  
ECG — electrocardiography; eGFR — estimated glomerular filtration rate; ELISA — enzyme-linked immunosorbent assay;  
PVI — pulmonary vein isolation; TIA — transient ischaemic attack; TTE — transthoracic echocardiography; VHD — valvular heart disease
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Periprocedural management
All patients were anticoagulated with vitamin K antagonists for 
at least three months prior to PVI. Transoesophageal echocar-
diography was performed to exclude the potential presence of 
LA appendage thrombus within 24 h preceding the procedure. 
Three or four venous accesses were obtained by Seldinger 
technique: for the left (a 6-F sheath — quadripolar electrode 
placed in the right ventricle) and right femoral veins (two 8-F 
sheaths — circular mapping and radiofrequency ablation 
electrodes or one 14-F sheath for cryoablation balloon) and 
for the right jugular vein (a 6-F sheath — decapolar electrode 
for coronary sinus catheterisation). Rotational angiography of 
LA was performed at the beginning of the procedure (contrast 
medium injection to pulmonary artery during fast right ven-
tricular stimulation). Following transseptal puncture, three-di-
mensional electro-anatomical mapping was performed using 
the CARTO®3 system (Biosense Webster, Diamond Bar, CA, 
USA) in patients undergoing radiofrequency ablation. PVI 
was achieved by means of either radiofrequency ablation 
with the ThermoCool® SmartTouch® SF catheter (Biosense 
Webster, Diamond Bar, CA, USA) (n = 61, 88.4%) or with 
balloon cryoablation (n = 8, 11.6%) using an Arctic Front 
Advance™ catheter (Medtronic, Minneapolis, MN, USA). PVI 
was performed under the guidance of a circular mapping elec-
trode — Lasso (Biosense Webster, Diamond Bar, CA, USA) or 
Achieve (Medtronic, Minneapolis, MN, USA). The procedure 
was performed with international normalised ratio (INR) up 
to 2.5 (preferably 2.0–2.5). All the patients received an IV 
bolus of unfractioned heparin (100 IU/kg) immediately after 
transseptal puncture and continuous infusion of 2000 IU/h 
through a transseptal sheath to obtain an activated clotting 
time (ACT) of over 300 s. The ACT was measured at 30-min 
intervals during the procedure. Postprocedural 24-h heparin 
infusion under the control of ACT was continued in patients 
with INR < 2 during the procedure. The next vitamin K 
antagonist dose was administered 4 h after the procedure to 
obtain an INR within the range of 2.0–3.0 the following day. 
Statistical analysis
Statistical analysis was performed using Statistica 10.0 (Stat-
Soft, Krakow, Poland) software. Quantitative variables were 
presented as the mean ± standard deviation (SD) or median 
(interquartile range), and qualitative parameters were ex-
pressed as numbers and percentages. The type of distribution 
was verified using Shapiro-Wilk test. In case of normally-dis-
tributed variables, Student t test for unpaired samples was 
used, while the Mann-Whitney U test was implemented 
in non-normally distributed parameters. The association 
between initial renalase concentration and AF recurrence 
was established using receiver operating characteristic curve 
(ROC) analysis. Multiple regression analysis covered all the 
variables with p < 0.1 in the univariate regression model. 
A p-value < 0.05 was regarded as statistically significant. 
RESULTS
General characteristics
The demographic and clinical characteristics of the study 
group are shown in Table 1. In brief, the study group consisted 
of 69 patients with either paroxysmal (89.9%) or persistent 
AF (10.1%), who were referred for catheter-based radiofre-
quency PVI. The majority of patients were men (66.7%) and 
the median age was 58 years. The study group was charac-
terised by high symptomatology of AF (median European 
Heart Rhythm Association [EHRA] class 3) and low ischaemic 
stroke risk (median CHA2DS2-VASc score of one point). All of 
the study participants received vitamin K antagonist as their 
anticoagulation regimen. In the course of in-hospital stay, one 
patient exhibited moderate access site haematoma without 
a decrease in haemoglobin concentration.
Study versus control group
The intergroup comparison is presented in Table 2. Patients 
in both groups were characterised by comparable rates of 
comorbidities, such as arterial hypertension and diabetes. Pa-
tients in the study group had lower white blood cell count 
(p = 0.006) and platelet count (p = 0.056). Plasma renalase 
concentration was markedly higher in the study group than 
in the control group (27.99 vs. 21.48 μg/mL, p = 0.004).
Renalase in the study group
In the study group, subjects with paroxysmal AF had mark-
edly higher levels of peripheral vein renalase (28.77 ± 
± 9.48 vs. 19.05 ± 12.60 μg/mL, p = 0.048) in comparison 
to patients with persistent AF (Table 3).
Plasma renalase levels did not differ depending on the 
presence or absence of arterial hypertension (p = 0.431 and 
p = 0.229, respectively), type 2 diabetes mellitus (p = 0.893 and 
p = 0.381), coronary artery disease (p = 0.375 and p = 0.152), 
or obesity (p = 0.282 and p = 0.117). However, cigarette 
smokers exhibited lower levels of plasma renalase concentra-
tion (20.05 ± 12.02 vs. 28.50 ± 9.00 μg/mL, p = 0.026).
Patients with in-hospital episodes of AF during the acqui-
sition of samples directly preceding PVI had lower renalase 
level (24.496 vs. 29.66 μg/mL; p = 0.04) and simultane-
ously had a greater LA volume index (31.5 vs. 25.0 mL/m2, 
p = 0.041) and less negative global four-chamber LA strain 
(–10.9 vs. –14.2, p = 0.03).
Atrial fibrillation severity  
and plasma renalase concentration
The distribution of different clinical variables within four 
quartiles of plasma renalase concentration in the study group 
is denoted in Table 4 and Figure 2. In comparison to the 
fourth quartile, patients within the lowest quartile of renalase 
concentration had greater mean and maximal heart rate on 
preprocedural electrocardiographic monitoring, greater AF 
burden and LA diameter, and less negative global longitudinal 
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Table 1. Demographic, clinical, and procedural characteristics 
of the study group
Variable Value
Male sex 46 (66.7)
Age [years] 58 (50; 62)
Body mass index [kg/m2] 28.7 ± 4.4
CHA2DS2-VASc [points] 1 (1; 2)
EHRA score 3 (2; 3)
Persistent AF 7 (10.1)
History of PVI 2 (2.9)
History of CV 17 (24.6)
Mode of PVI: RF 61 (88.4)
Cryoablation 8 (11.6)
AF duration: 0–5 years 29 (42.0)
5–10 years 24 (34.8)
>10 years 16 (23.2)
Cigarette smoking 28 (40.6)
Obesity 22 (31.9)
Coronary artery disease 14 (20.3)
Arterial hypertension 41 (59.4)
Hyperlipidaemia 45 (65.2)
Type 2 diabetes 12 (17.4)
Thyroid disease 19 (27.5)
ACEI 36 (52.2)
b-blockers 49 (71.0)





Duration of in-hospital Holter monitoring [h] 19.0 (17.8; 19.3)
Maximal HR [bpm] 100 (83; 115)
Mean HR [bpm] 66 (57; 75)
Minimal HR [bpm] 52 (46; 55)
AF burden [%] 22.6 ± 38.7
Maximal HR during AF [bpm] 134.5 (112.0; 147.0)
Patients with in-hospital AF episodes 20 (28.9)
LA volume index [mL/m2] 25.6 ± 9.4
LVEF [%] 58.6 ± 4.4
Global four-chamber LA LS –11.5 ± 4.7
Global two-chamber LA LS –12.0 ± 4.9
E/E’ 8.2 ± 2.9
Carotid intima-media thickness [mm] 0.65 (0.57; 0.86)
Platelet count [×1000/mm3] 196.7 ± 46.3
White blood cell count [×1000/mm3] 5.9 ± 1.3
Haemoglobin concentration [g/dL] 14.2 ± 1.3
Thyroid-stimulating hormone [µIU/mL] 2.3 (0.99; 3.1)
Total cholesterol [mg/dL] 183.29 ± 44.55
Serum creatinine concentration [mg/dL] 0.91 ± 0.15
eGFR [mL/min/1.73 m2] 82.91 ± 8.31
Six-month ECG Holter monitor duration [h] 166.5 (144.4; 168.5)
Six-month follow-up — AF burden [%] 7.1 ± 20.7
Six-month follow-up — patients with AF episodes 12 (17.4)
Plasma renalase concentration [µg/mL] 27.99 ± 10.01
Data are shown as absolute count and percentage, or median and 
interquartile range, or mean ± standard deviation. ACEI — angiotensin 
converting enzyme inhibitor; AF — atrial fibrillation; CV — electrical 
cardioversion; ECG — electrocardiographic; E/E’ — the ratio of mitral 
peak velocity of early filling (E) to early diastolic mitral annular velocity 
(E’); eGFR — estimated glomerular filtration rate; EHRA — European 
Heart Rhythm Association; HR — heart rate; LA — left atrial; LS —  
longitudinal strain; LVEF — left ventricular ejection fraction; PVI — 
pulmonary vein isolation; RF — radiofrequency
LA strain (Table 4, Fig. 2). The rest of the echocardiographic 
indices of LA remodelling, and LA and left ventricular systolic 
and diastolic functions were comparable between the first and 
fourth quartile of plasma renalase concentration.
After exclusion of patients with persistent AF, patients 
with plasma renalase concentration within the first quar-
tile were characterised by a trend towards higher mean 
heart rate (69.5 [57; 82] bpm vs. 61.5 [57; 66] bpm, 
p = 0.072), less negative four-chamber global LA strain 
(–9.7 ± 4.6 vs. –13.4 ± 5.7, p = 0.11), and a trend towards 
greater LA diameter (40.3 ± 2.2 mm vs. 38.2 ± 3.5 mm, 
p = 0.087) in comparison with the highest levels of plasma 
renalase (fourth quartile).
Renalase and AF recurrence  
at six-month follow-up
At six-month follow-up, episodes of AF were documented in 
12 (17.4%) patients who underwent the initial PVI procedure. 
Patients with evidence of AF on seven-day continuous electro-
cardiogram monitoring at six-month follow-up were charac-
terised by comparable levels of plasma renalase concentration 
(p = 0.38). The ROC curve analysis showed that plasma 
renalase concentration (area under curve [AUC] = 0.614, 
95% confidence interval [CI] 0.473–0.743, p = 0.216; Fig. 3) 
did not have sufficient power for prediction of AF recurrence. 
Univariate and multivariate regression analyses
Linear regression analysis demonstrated that plasma renalase 
concentration negatively correlated with mean heart rate, 
maximal heart rate during AF episode and AF burden, LA di-
ameter, and global longitudinal four-chamber strain (Table 5). 
Conversely, renalase level positively corresponded with mean 
platelet volume (Table 5).
According to stepwise multivariate regression analysis, 
global longitudinal four-chamber LA strain was the only 
independent predictor of plasma renalase concentration 
(b = –0.425, p = 0.0045; adjusted coefficient of determina-
tion R2 = 0.18). 
DISCUSSION
The current research shed light on the association between 
plasma renalase level and the markers of structural and electri-
cal LA remodelling and AF burden. It was documented that 
patients with evidence of AF have substantially higher plasma 
renalase concentration (Table 2). Although plasma renalase 
did not accurately predict AF recurrence at six months after 
percutaneous PVI, patients with plasma renalase within the 
lowest quartile were characterised by higher AF burden during 
index hospitalisation, greater LA diameter, and less negative LA 
global longitudinal strain (Fig. 2, Table 4). Moreover, patients 
with paroxysmal AF had higher levels of plasma renalase con-
centration than the subgroup with persistent AF, while current 
AF episode corresponded with lower levels of plasma renalase.
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Table 3. Comparison of patients with paroxysmal and persistent atrial fibrillation in the study group
Variable Paroxysmal AF (n = 62) Persistent AF (n = 7) p
Male sex 41 (89.1) 5 (71.4) 0.361
Age [years] 59 (50; 62) 46 (39; 57) 0.092
Body mass index [kg/m2] 28.9 ± 4.5 27.7 ± 2.8 0.528
Arterial hypertension 37 (59.7) 4 (57.1) 0.551
Type 2 diabetes 12 (19.4) 1 (14.3) 0.296
Coronary artery disease 13 (21.0) 2 (16.7) 0.640
eGFR [mL/min/1.73 m2] 82.6 ± 8.4 84.8 ± 8.0 0.544
Haemoglobin concentration [g/dL] 14.1 ± 1.2 14.9 ± 2.1 0.143
Platelet count [×1000/mm3] 193.8 ± 44.7 211.3 ± 51.2 0.370
CHA2DS2-VASc [points] 1 (1; 2) 1 ( 1; 2) 0.646
EHRA score 3 (2; 3) 2 (2; 2) 0.002
Maximal HR [bpm] 100 (83.5; 113) 147.5 (113; 153.5) 0.028
Mean HR [bpm] 66 (57; 73) 75.5 (65.5; 81.5) 0.364
Minimal HR [bpm] 51.5 (45.5; 55.0) 55.0 (51.5; 59.0) 0.459
LA diameter [mm] 39.0 ± 3.9 41.4 ± 5.2 0.210
LA volume index [mL/m2] 25.1 ± 9.4 27.9 ± 5.5 0.608
LVEF [%] 58.6 ± 4.3 58.0 ± 5.7 0.769
Global four-chamber LA LS –11.8 ± 4.8 –6.9 ± 2.3 0.075
Global two-chamber LA LS –12.3 ± 4.8 –6.3 ± 0.5 0.018
E/E’ 8.2 ± 3.1 7.7 ± 2.3 0.768
Plasma renalase concentration [µg/mL] 28.77 ± 9.48 19.05 ± 12.60 0.048
Data are shown as number (percentage), median and interquartile range or mean ± standard deviation. Abbreviations — see Table 1
Table 2. Comparison of study and control groups in terms of different clinical variables and peripheral vein renalase concentration
Variable Study group 
— patients with AF 
(n = 69)
Control group  
— patients without AF 
(n = 15)
p
Male sex 46 (66.7) 9 (60.0) 0.416 a
Age [years] 58 (50; 62) 57 (53; 58) 0.900 b
Body mass index [kg/m2] 28.7 ± 4.4 31.0 ± 4.2 0.426 c
Arterial hypertension 41 (59.4) 10 (66.7) 0.415 a
Type 2 diabetes 12 (17.4) 3 (20.0) 0.531 a
Platelet count [×1000/mm3] 196.7 ± 46.3 220.9 ± 30.2 0.056 b
White blood cells [×1000/mm3] 5.9 ± 1.3 7.0 ± 2.1 0.006 c
Haemoglobin concentration [g/dL] 14.2 ± 1.3 14.5 ± 1.4 0.387 c
Serum creatinine concentration [mg/dL] 0.91 ± 0.15 0.88 ± 0.2 0.770 c
eGFR [mL/min/1.73 m2] 82.9 ± 8.3 90.7 ± 16.9 0.390 c
Plasma renalase concentration [µg/mL] 27.99 ± 10.01 21.48 ± 5.01 0.004 b
Data are shown as number (percentage), median and interquartile range, or mean ± standard deviation. Conversion factors to SI units are as 
follows: for creatinine [in mg/dL] — 88.4; for haemoglobin [in g/dL] — 10; for total cholesterol [in mg/dL] — 0.02586. Abbreviations — see Table 1 
aFisher’s exact test; bMann-Whitney U test; cStudent’s t-test 
Our study is the first report in the literature regarding 
renalase concentration in the population of patients with AF, 
thus it cannot be directly compared to any former studies. The 
present findings comply with previous reports suggesting 
the role of renalase in promoting cardiomyocyte survival 
[25] via PMCA4b receptor and mitogen-activated protein 
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Table 4. Distribution of various clinical parameters depending on the quartile of peripheral vein renalase concentration
Variable Plasma renalase concentration p* p**
1st quartile 2nd quartile 3rd quartile 4th quartile
Age [years] 59 (50; 65) 56 (42; 58) 59 (55; 62) 61 (52; 63) 0.716 b 0.191 b
Body mass index [kg/m2] 29.2 ± 4.0 30.1 ± 4.2 26.5 ± 3.8 29.0 ± 5.2 0.792 a 0.062 a
CHA2DS2-VASc [points] 1.5 (1; 3) 1.0 (1; 2) 1.0 (1; 2) 1.0 (1; 2) 1.0
 b 0.588 b
EHRA score 2 (2; 3) 2 (2; 3) 3 (3; 3) 3 (2; 3) 0.114 b 0.038 b
Maximal HR [bpm] 120.5 (86.5; 153.0) 107.5 (88; 114) 93.5 (77; 112) 91 (86; 101) 0.037 b 0.158 b
Mean HR [bpm] 70.0 (57.0; 81.5) 70.5 (62; 76) 62.5 (56; 70) 61.0 (57; 66) 0.029 b 0.133 b
Minimal HR [bpm] 53 (47; 55) 53.5 (48; 56) 50.5 (44; 55) 50 (46; 52) 0.288 b 0.535 b
AF burden [%] 36.9 ± 44.5 28.0 ± 43.2 18.3 ± 37.5 9.3 ± 27.6 0.027 a 0.162 a
Maximal HR during AF [bpm] 143.3 (146.5; 159.0) 134 (121; 142) 129 (112; 144) 104 (39.5; 137.5) 0.088 b 0.231 b
Six-month follow-up — AF burden [%] 14.9 ± 29.6 1.7 ± 6.3 4.8 ± 11.8 7.9 ± 26.6 0.271 a 0.366 a
LA diameter [mm] 41.1 ± 2,9 39.1 ± 4.2 38.7 ± 4.8 37.9 ± 3.5 0.011 a 0.135 a
LA volume index [mL/m2] 28.6 ± 10.2 21.9 ± 8.7 26.7 ± 12.0 26.4 ± 6.8 0.565 a 0.333 a
LVEF [%] 58.5 ± 5.0 58.9 ± 3.5 57.6 ± 4.7 59.4 ± 4.4 0.675 a 0.824 a
Global four-chamber LA LS –9.4 ± 4.2 –10.1 ± 4.4 –13.0 ± 3.6 –13.5 ± 5.7 0.082 a 0.064 a
Global two-chamber LA LS –10.3 ± 4.9 –11.4 ± 5.8 –13.3 ± 4.0 –13.0 ± 4.4 0.156 a 0.242 a
E/E’ 8.7 ± 4.4 8.3 ± 2.3 7.7 ± 2.4 8.1 ± 3.0 0.565 a 0.853 a
Intima-media thickness [mm] 0.73 (0.63; 1.4) 0.6 (0.55; 1.3) 0.6 (0.5; 0.7) 0.65 (0.6; 0.9) 0.894 b 0.532 b
Data are shown as median and interquartile range or mean ± standard deviation. Abbreviations — see Table 1 
*1st vs. 4th quartile — Student t test (a) or Mann-Whitney U test (b); **ANOVA test (a) or Kruskal-Wallis test (b)
kinase signalling pathway [26]. Li et al. [25] demonstrated 
that myocardial ischaemia-reperfusion injury led to lower 
myocardial renalase expression [25]. Renalase knock-out rats 
experienced greater extent of necrosis and apoptosis, which 
was prevented by pretreatment with recombinant renalase 
[25]. Consequently, less pronounced expression of renalase 
in patients with more advanced disease (e.g. greater LA diam-
eter) may reflect impaired activation of protective mechanism. 
In addition, renalase was previously thought to be engaged 
in catecholamine metabolism and inversely correlated with 
peripheral and central blood pressure [20–22].
Our results support the notion that renalase depletion 
represents a marker of disease progression (Table 3) rather than 
a discriminator of AF in the broad population because patients 
with AF had greater plasma renalase levels than the matched 
controls (Table 2). Undoubtedly, periprocedural plasma renal-
ase did not herald recurrence of AF at six-month observation 
based on our findings (Fig. 3). Several other biomarkers were 
previously shown to predict maintenance of sinus rhythm. 
The largest GISSI-AF study by Latini et al. [16] performed 
on 382 patients with paroxysmal AF or after cardioversion 
for persistent AF provided evidence that high-sensitivity car-
diac troponin T, mid-range pro-A-type natriuretic peptide, 
N-terminal pro–B-type natriuretic peptide, and C-terminal 
pro-endothelin-1 were positively associated with AF recur-
rence. This confirms that well-established markers of myo-
cardial necrosis (troponin) and atrial wall stress (natriuretic 
peptides) are better related with the long-term outcomes of 
rhythm control strategy [16]. In this study, a stable precursor 
of antidiuretic hormone, namely copeptin, failed to predict 
the relapse of AF [16]. 
In patients undergoing the PVI procedure, Takemoto et 
al. found that intracardiac galectin-3 concentration adequately 
identified patients at risk of AF recurrence following a single 
PVI [18]. Inhibition of this extracellular mediator of fibrosis in 
an animal model led to decreased AF burden and a tendency 
towards more rapid AF termination [18]. 
The results of the current study provided evidence 
that plasma renalase levels were paradoxically lower in 
the control group without the diagnosis of AF. Presumably, 
the prothrombotic and proinflammatory state of AF may 
upregulate the production of antiapoptotic renalase as 
a counter-regulatory mechanism [26]. Conversely, among 
individuals with confirmed AF, lower counter-regulatory 
response or depleted renalase spillover were associated with 
more advanced disease.
Taking into consideration the results of the study, circu-
lating renalase seems to be an indicator of the stage of LA 
remodelling. Its concentration is strongly dependent on the 
systolic function of LA; global four-chamber LA longitudinal 
strain was the only independent predictor of plasma renalase 
concentration (b = –0.425, p = 0.0045). Conversely, renalase 
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Table 5. Univariate regression analysis of different predictors of 
peripheral vein renalase concentration
Renalase vs. Renalase  
— peripheral vein
b p
Male sex –0.02 0.899
Age 0.10 0.378
Body mass index –0.11 0.366
CHA2DS2-VASc score –0.01 0.933
EHRA score 0.23 0.057
Arterial hypertension –0.10 0.431
Type 2 diabetes –0.03 0.888
Coronary artery disease 0.11 0.375
Hyperlipidaemia 0.20 0.107
In-hospital AF episodes –0.21 0.134
Maximal HR –0.25 0.070
Mean HR –0.30 0.033
AF burden –0.32 0.023
Paroxysmal AF 0.20 0.104
Maximal HR during AF episode –0.42 0.050
Mean platelet volume 0.25 0.038
Serum creatinine concentration 0.10 0.415
eGFR –0.13 0.299
Intima-media thickness 0.03 0.874
LVEF 0.02 0.866
E/E’ –0.07 0.620
LA diameter –0.29 0.019
LA volume index 0.02 0.880
LV end-diastolic diameter –0.25 0.051
Global four-chamber LA LS –0.36 0.008
Global two-chamber LA LS –0.27 0.062
b — univariate regression coefficient; other abbreviations — see Table 1 
Figure 3. Receiver operating characteristic curve of the prediction 
of atrial fibrillation (AF) recurrence during six-month follow-up 
by periprocedural peripheral-vein renalase concentration
Figure 2. Atrial fibrillation (AF) burden, left atrial diameter, and 
four-chamber left atrial (LA) global longitudinal strain with re-
spect to the quartile of peripheral vein renalase concentration; 
A. AF burden in relation to quartile of renalase concentration; 
B. LA diameter in relation to quartile of renalase concentra-
tion; C. Four-chamber LA global longitudinal strain in relation 
to quartile of renalase concentration; CI — confidence interval
www.kardiologiapolska.pl
Renalase and atrial fibrillation
1239
is not specific for AF, nor does it identify patients with a his-
tory of AF or reflect possible maintenance of sinus rhythm.
The main limitation of the study is a small study popula-
tion. In particular, the analysis involved only seven patients 
with persistent AF, which is characterised by more pronounced 
LA adverse remodelling. In addition, the authors did not 
investigate the temporal variability of plasma renalase con-
centration. The response to PVI was assessed by means of 
seven-day Holter electrocardiographic monitoring, which 
confers possible risk of underestimation of AF recurrence, 
as compared to e.g. home telemonitoring or implantable 
loop recorder.
In conclusion, low plasma renalase levels may be associ-
ated with impaired rate control, higher AF burden, and more 
advanced LA remodelling in patients with AF referred for PVI. 
Plasma renalase concentration failed to predict recurrence of 
AF in the six-month observation.
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